ABSTRACT
Specific serological tests are mandatory for reliable SARS-CoV-2 seroprevalence studies but assay specificity may vary considerably between populations due to interference of immune responses to other pathogens. Here, we assess the false positive rates obtained with four commercially available IgG ELISAs in serum panels originating from three different African countries.
Article summary line Several commercially available SARS-CoV-2 ELISAs show limited specificity when applied to serum panels of African origin
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: PE has a patent EP2492689 issued; no other competing interests.
Funding Statement
The study was conducted within the framework of the project East African Community (EAC) regional network of public health reference laboratories for communicable diseases (https://mobilelabs.eac.int/) funded by the Federal Republic of Germany through the German Development Bank (KfW). The study was supported by the German Research Foundation (DFG, GU 883/4-1 and GU 883/5-1), by the German Federal Ministry of Health through support of the WHO Collaborating Centre for Arboviruses and Hemorrhagic Fever Viruses at BNITM (agreement ZMV I1-2517WHO005), through the Global Health Protection Program (agreement ZMV I1-2517GHP-704), and through the COVID support agreement ZMVI1-2520COR001. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies complied with the Declaration of Helsinki. Written informed consent was obtained from all individuals or, in case of minors, from parents or legal guardians before enrollment. Data privacy protection was guaranteed by anonymization of samples. Collection of samples has been approved by the Ethics Committees of the Kwame Nkrumah University of Science and Technology, Kumasi/Ghana (CHRPE/AP/427/13 and CHRPE/101/09), the Comite d ethique de la Vice Primature Chargee de la Sante Publique, Antananarivo/Madagaskar (No. 051-CE/MINSAN), the Irrua Specialist Teaching Hospital, Irrua/Nigeria (ISTH/HREC/20171019/28), the Hospital Rosario Pumarejo de Lopez of Valledupar/Colombia, the Lao Peoples Democratic Republic (No. 030/NECHR), and the Medical Association Hamburg/Germany (No. PV4608)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data relevant for the study are presented in the manuscript and its appendix.
